Marshall Wace, LLP Gracell Biotechnologies Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.43 - $10.04 $177,331 - $732,679	72,976 Added 61.07%	192,465 $1.93 Million
Q3 2023 Nov 14, 2023	SELL	$2.83 - $4.9 $300,373 - $520,081	-106,139 Reduced 47.04%	119,489 $344,000
Q2 2023 Aug 14, 2023	BUY	$1.45 - $6.07 $327,160 - $1.37 Million	225,628 New	225,628 $859,000
Q2 2022 Aug 15, 2022	SELL	$1.95 - $5.5 $75,566 - $213,136	-38,752 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.83 - $5.52 $88,894 - $268,139	-48,576 Reduced 55.62%	38,752 $89,000
Q4 2021 Feb 14, 2022	BUY	$5.65 - $14.9 $96,174 - $253,627	17,022 Added 24.21%	87,328 $528,000
Q3 2021 Nov 15, 2021	SELL	$9.91 - $14.84 $46,854 - $70,163	-4,728 Reduced 6.3%	70,306 $975,000
Q2 2021 Aug 13, 2021	SELL	$9.75 - $18.42 $247,640 - $467,849	-25,399 Reduced 25.29%	75,034 $976,000
Q1 2021 May 17, 2021	BUY	$14.7 - $30.57 $1.48 Million - $3.07 Million	100,433 New	100,433 $1.55 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.